UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
 
 
FORM 12b-25/A
(Amendment No. 1)
 
NOTIFICATION OF LATE FILING
 
 
     
(Check one):    
  
☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K   ☒ Form 10-Q
☐  Form 10-D     ☐  Form N-SAR     ☐  Form N-CSR
   
   
For Period Ended: September 30, 2013
   
   
☐Transition Report on Form 10-K
   
☐  Transition Report on Form 20-F
   
☐  Transition Report on Form 11-K
   
☐  Transition Report on Form 10-Q
   
☐  Transition Report on Form N-SAR
   
   
For the Transition Period Ended:
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Part II (except for Item 5) and certain exhibits in Part IV, Item 15, as specified in the Form 10-K filed as described below.
 
 
PART I — REGISTRANT INFORMATION
Biozone Pharmaceuticals, Inc.

Full Name of Registrant
 
 
 
 
 
Former Name if Applicable
550 Sylvan Avenue, Suite 101
Address of Principal Executive Office (Street and Number)
Engelwood Cliffs, NJ 07632
City, State and Zip Code
 
 
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
       
       
 
(a)
  
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
☒
(b)
  
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
 
(c)
  
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 

PART III — NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The Company has been engaged in negotiating a significant transaction that has required significant attention from the Chief Executive Officer/Chief Financial Officer and as a result he has not had the time to finalize the report.
 
 
Part IV - Other Information
1.  
Name and telephone number of person to contact in regard to this notification
 
Elliot Maza
201-608-5101
(Name)
(Area Code)
(Telephone Number)
 
2.  
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes 
 X 
  No 
      
 
 
 
 
 
3.  
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
Yes 
 X 
  No 
      
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

See Annex A



                    Biozone Pharmaceuticals, Inc.                    
(Name of Registrant as Specified in Charter)
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
     
Date: November 12, 2013
By
/s/ Elliot Maza
 
Name:
Elliot Maza
 
Title:
Chief Executive Officer and Chief Financial Officer
 
    
 
 
 
 

 
Annex A to 12b-25/A No. 1


The Issuer will report (i) gross profit of $1,109,821 for the third quarter 2013 compared to $1,906,226 for the third quarter 2012, and (ii) a net loss from continuing operations of $6,058,242 for the third quarter 2013 compared to $122,540 for the third quarter 2012.